Onco Actu du 20 novembre 2015

	4. Dépistage, diagnostic et pronostic
Companion Diagnostics? For Cancer Care, We Need Better Ones [Forbes] Some companion diagnostics simply are not ready for prime time, to borrow language from a recent tweet by Dr. Eric Topol, a cardiologist and technophile. He pointed to a critical article in JAMA Oncology concerning tools for assessing a protein, PD-L1, and related biomarkers.
	4.12 Biopsies liquides
Highly Accurate microRNA Sensor for Cancer Detection [Medgadget] The researchers used the device to detect the levels of microRNA-10b in pancreatic cancer patients, a biomarker for the disease. They were also able to do the same within exosomes, the somewhat mysterious vesicles that are released by cells and found seemingly in most parts of the body where bilogical fluid is present. The device will allow further studies into the role of mRNAs within the body.
	5. Traitements
Dabrafenib Produces Rapid Shrinkage of Recurrent, BRAF-mutant Papillary Craniopharyngioma [ESMO] "This has the potential of completely changing the management of papillary craniopharyngiomas, which can cause lifelong problems for patients - including visual defects, impaired intellectual function, and pituitary and other hormonal dysfunction."
How Genomics Is Shaping Precision Medicine in Oncology [National Cancer Institute] In this post, Louis M. Staudt, M.D., Ph.D., director of NCI’s Center for Cancer Genomics, discusses the principles of precision medicine and how they are being applied to improve the treatment of lymphoma.
	5.2 Pharma
Ex-Sanofi CEO Gets $600M to Drug Hunt With Boston Pharma [Xconomy] Boston Pharma calls this strategy “innovative,” but it is reminiscent of several previous biotech projects.
Brent Saunders Makes His Vague, Tedious Case [In the Pipeline] This article’s not going to make anyone in the Pfizer labs feel any better this morning.
Former Sanofi CEO Viehbacher to bankroll new drugs [Reuters] Chris Viehbacher, ousted last year after six years as CEO of French drugmaker Sanofi, is settling into a new job that involves picking promising experimental drugs before they have been tested in human trials.
	5.4 Traitements - Economie
Cancer Society Asks Regulators To Limit Insurers' Charges For Key Drugs [NPR] Those drugs include some well-known treatments, such as Gleevec for certain types of leukemia and Herceptin for breast cancer, and even some generics.
Consultation now open on plans to reform Cancer Drugs Fund [NICE] The proposals are aimed at providing patients with access to promising new medicines while the evidence is still emerging, in a financially sustainable way.
Reforming NICE and the Cancer Drugs Fund – four key changes we want to see [Cancer Research UK] So we’re extremely pleased – and relieved – that today, NHS England and NICE have set out proposals to reform the system, which are now open for consultation. We will need to look at these proposals in detail. But in the meantime, here are the changes we think are needed.
Cancer Drugs Fund plans 'to speed up access' to drugs [BBC News] "The new Cancer Drugs Fund offers a route for sorting out the wheat from the chaff, so that patients in England get faster access to the genuinely most promising new treatments."
Expensive cancer drugs may be offered to NHS patients during trial period [The Guardian] Under NHS England proposals, patients will be given drugs normally too expensive for the NHS while data is collected to establish their value.
	6.1 Observation
Weekday of surgery affects oesophageal cancer surgery prognosis [Karolinska Institutet] Patients who undergo surgery for oesophageal cancer early in the week – on a Monday or Tuesday – have a higher chance of long-term survival than those who have surgery at the end of the working week.
Social and economic factors tied to pancreatic cancer surgery, survival [Reuters] For the new study, the researchers looked at what factors are tied to people with pancreas cancer getting resections, and whether those factors are also linked to how long a person lives after surgery.
	6.10 Politiques
France proposes 'Made in EU" drug labels [STAT] The push appears to be an attempt by the French government to bolster its domestic pharmaceutical industry, which includes Sanofi, one of the world’s largest drug makers.